Gabriel Brooks - 18 Oct 2026 Form 4 Insider Report for Solid Biosciences Inc. (SLDB)

Reporting relationship: Chief Medical Officer
Issuer ticker: SLDB
Reported as of: 18 Oct 2026
Net transaction value: -$24,582
SEC form: 4
Accepted by SEC: 20 Oct 2026, 16:05:05 UTC
Prior SEC filing: 18 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Kimberly Cornwell as attorney-in-fact for Gabriel Brooks

Filing notes and source

Key filing fact

Gabriel Brooks filed Form 4 for Solid Biosciences Inc. (SLDB) on 20 Oct 2026.

Key facts

This page summarizes Gabriel Brooks's Form 4 filing for Solid Biosciences Inc. (SLDB).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 20 Oct 2026, 16:05.

Change

Previous filing in this sequence was filed on 18 Feb 2026.
Current net transaction value: -$24,582.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001997809 Primary reporting owner

Brooks Gabriel

Relationship: Chief Medical Officer
Address: C/O SOLID BIOSCIENCES INC., 500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN
Signature: /s/ Kimberly Cornwell as attorney-in-fact for Gabriel Brooks
Signature date: 20 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SLDB transaction

Common Stock

Options Exercise

Transaction value
Shares: +9,750
Change %: +11%
Price
Shares after: 101,615
Date: 18 Oct 2026
Ownership: Direct
Footnotes: F1, F2

SLDB transaction

Common Stock

Sale

Transaction value: -$24,582
Shares: -4,374
Change %: -4.3%
Price: $5.62
Shares after: 97,241
Date: 19 Oct 2026
Ownership: Direct
Footnotes: F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SLDB transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -9,750
Change %: -50%
Price: $0.000000^*
Shares after: 9,750
Date: 18 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 9,750
Exercise price
Footnotes: F1, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

Footnote F2

Includes 2,399 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on May 29, 2026.

Footnote F3

This sale was made to cover withholding taxes following the vesting of previously granted RSUs pursuant to a durable automatic sale instruction letter adopted by Dr. Brooks on August 15, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Dr. Brooks.

Footnote F4

The RSUs were granted on October 18, 2023 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.